Brain targeted drug delivery systems : a focus on nanotechnology and and nanoparticulates / edited by Huile Gao, Xiaoling Gao
3.2. Improving physicochemical properties of CNS-active drugs3.3. Drug modification with targeting moieties; 3.4. Nanocarrier-based drug delivery; 3.5. Cell-based drug delivery; 4. Future perspectives; References; Chapter 4: In vitro and in vivo models of BBB to evaluate brain targeting drug delivery; 1. Introduction; 2. The neurovascular unit; 2.1. Endothelial cells; 2.2. Pericytes; 2.3. Astrocytes; 2.4. Molecular structure of the junction; 2.4.1. Tight junctions; 2.4.2. Adherens junction; 3. Movement through the blood-brain barrier; 3.1. Passive diffusion; 3.2. Carrier-mediated transport..
3.5. Accessory proteins3.6. Pericytes; 3.7. Neurons; 3.8. Extracellular matrix; 4. Role of astrocytes; 5. Transportation across blood-brain barrier; 6. Types of transport systems at blood-brain barrier; 6.1. Amino acid transport; 6.2. Hexose transport system; 6.3. Monocarboxylate transporter system; 6.4. Organic anion transporter family; 6.5. Organic cation transporter (OCT and OCTN) family; 6.6. Transport of nucleosides; 6.7. Transport of peptides; 6.8. Transport of macromolecules; 6.9. Transport of ions; 6.10. Transcytosis of macromolecules; 7. Conclusions; References..
3.3. Active efflux pumps3.4. Transcytosis; 3.5. Cell-mediated transport; 4. In vitro models of BBB for assessing drug delivery; 4.1. Methods for measuring permeability; 4.1.1. TEER (trans-endothelial electric resistance) measurement; 4.1.2. FITC-dextran and sodium fluorescein; 4.1.3. Lucifer yellow; 4.1.4. Evans blue dye; 4.1.5. Horseradish peroxidase (HRP); 4.1.6. Mannitol/sucrose/inulin (radiolabeled); 4.2. In vitro models; 4.2.1. Noncell-based (synthetic) in vitro models; 4.2.1.1. Immobilized artificial membrane (IAM) chromatography; 4.2.1.2. Parallel artificial membrane permeability assay..
Chapter 3: Recent progress in blood-brain barrier transportation research1. Introduction; 2. Overview of the transport mechanisms at the BBB; 2.1. Carrier-mediated transcytosis; 2.1.1. Glucose transporters; 2.1.2. Large neutral amino acid transporter 1; 2.1.3. Monocarboxylate transporter 1; 2.2. Receptor-mediated transport; 2.2.1. Transferrin receptor; 2.2.2. Insulin receptor; 2.2.3. Low-density lipoprotein receptor-related protein; 2.3. Adsorptive-mediated transcytosis; 3. Strategies for improving CNS delivery of therapeutics; 3.1. Enhanced paracellular transport..
Front Cover; Brain Targeted Drug Delivery Systems: A Focus on Nanotechnology and Nanoparticulates; Copyright; Dedication; Contents; Contributors; Preface; Chapter 1: Introduction and overview; 1. Is it possible to deliver drugs to brain?; 2. What's the major concerns of brain-targeted DDS?; 3. Conclusion; Part I: Physiology and principles for brain targeting drug delivery; Chapter 2: Anatomy and physiology of blood-brain barrier; 1. Introduction; 2. Concept of blood-brain barrier; 3. Neurovascular unit; 3.1. Occludin; 3.2. Claudin; 3.3. Adhesion junctions; 3.4. Junctional adhesion molecules..
Medienart: |
E-Book |
---|
Erscheinungsjahr: |
2019 |
---|---|
Erschienen: |
London: Academic Press ; 2019 |
Reproduktion: |
Online-Ausg. |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Gao, Huile [Sonstige Person] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
ISBN: |
---|
Umfang: |
1 Online-Ressource (1 online resource) |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
1039900550 |
---|
LEADER | 01000cam a22002652 4500 | ||
---|---|---|---|
001 | 1039900550 | ||
003 | DE-627 | ||
005 | 20240422234345.0 | ||
007 | cr uuu---uuuuu | ||
008 | 181106s2019 xxk|||||o 00| ||eng c | ||
020 | |a 012814002X |c : electronic bk. |9 0-12-814002-X | ||
020 | |a 9780128140024 |c : electronic bk. |9 978-0-12-814002-4 | ||
035 | |a (DE-627)1039900550 | ||
035 | |a (DE-599)GBV1039900550 | ||
035 | |a (ELSEVIER)on1055262923 | ||
035 | |a (EBP)027279219 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
044 | |c XA-GB | ||
050 | 0 | |a RS201.N35 | |
060 | 0 | |a QV 785 | |
072 | 7 | |a MED 071000 |2 bisacsh | |
084 | |a 58.28 |2 bkl | ||
245 | 1 | 0 | |a Brain targeted drug delivery systems |b a focus on nanotechnology and and nanoparticulates |c edited by Huile Gao, Xiaoling Gao |
264 | 1 | |a London |b Academic Press |c 2019 | |
300 | |a 1 Online-Ressource (1 online resource) | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a 3.2. Improving physicochemical properties of CNS-active drugs3.3. Drug modification with targeting moieties; 3.4. Nanocarrier-based drug delivery; 3.5. Cell-based drug delivery; 4. Future perspectives; References; Chapter 4: In vitro and in vivo models of BBB to evaluate brain targeting drug delivery; 1. Introduction; 2. The neurovascular unit; 2.1. Endothelial cells; 2.2. Pericytes; 2.3. Astrocytes; 2.4. Molecular structure of the junction; 2.4.1. Tight junctions; 2.4.2. Adherens junction; 3. Movement through the blood-brain barrier; 3.1. Passive diffusion; 3.2. Carrier-mediated transport. | ||
520 | |a 3.5. Accessory proteins3.6. Pericytes; 3.7. Neurons; 3.8. Extracellular matrix; 4. Role of astrocytes; 5. Transportation across blood-brain barrier; 6. Types of transport systems at blood-brain barrier; 6.1. Amino acid transport; 6.2. Hexose transport system; 6.3. Monocarboxylate transporter system; 6.4. Organic anion transporter family; 6.5. Organic cation transporter (OCT and OCTN) family; 6.6. Transport of nucleosides; 6.7. Transport of peptides; 6.8. Transport of macromolecules; 6.9. Transport of ions; 6.10. Transcytosis of macromolecules; 7. Conclusions; References. | ||
520 | |a 3.3. Active efflux pumps3.4. Transcytosis; 3.5. Cell-mediated transport; 4. In vitro models of BBB for assessing drug delivery; 4.1. Methods for measuring permeability; 4.1.1. TEER (trans-endothelial electric resistance) measurement; 4.1.2. FITC-dextran and sodium fluorescein; 4.1.3. Lucifer yellow; 4.1.4. Evans blue dye; 4.1.5. Horseradish peroxidase (HRP); 4.1.6. Mannitol/sucrose/inulin (radiolabeled); 4.2. In vitro models; 4.2.1. Noncell-based (synthetic) in vitro models; 4.2.1.1. Immobilized artificial membrane (IAM) chromatography; 4.2.1.2. Parallel artificial membrane permeability assay. | ||
520 | |a Chapter 3: Recent progress in blood-brain barrier transportation research1. Introduction; 2. Overview of the transport mechanisms at the BBB; 2.1. Carrier-mediated transcytosis; 2.1.1. Glucose transporters; 2.1.2. Large neutral amino acid transporter 1; 2.1.3. Monocarboxylate transporter 1; 2.2. Receptor-mediated transport; 2.2.1. Transferrin receptor; 2.2.2. Insulin receptor; 2.2.3. Low-density lipoprotein receptor-related protein; 2.3. Adsorptive-mediated transcytosis; 3. Strategies for improving CNS delivery of therapeutics; 3.1. Enhanced paracellular transport. | ||
520 | |a Front Cover; Brain Targeted Drug Delivery Systems: A Focus on Nanotechnology and Nanoparticulates; Copyright; Dedication; Contents; Contributors; Preface; Chapter 1: Introduction and overview; 1. Is it possible to deliver drugs to brain?; 2. What's the major concerns of brain-targeted DDS?; 3. Conclusion; Part I: Physiology and principles for brain targeting drug delivery; Chapter 2: Anatomy and physiology of blood-brain barrier; 1. Introduction; 2. Concept of blood-brain barrier; 3. Neurovascular unit; 3.1. Occludin; 3.2. Claudin; 3.3. Adhesion junctions; 3.4. Junctional adhesion molecules. | ||
533 | |a Online-Ausg. | ||
650 | 0 | |a Nanoparticles | |
650 | 0 | |a Drug delivery systems | |
650 | 0 | |a Nanoparticles | |
650 | 0 | |a Drug delivery systems | |
650 | 0 | |a Blood-brain barrier | |
650 | 2 | |a Glioma |x drug therapy | |
650 | 2 | |a Neurodegenerative Diseases |x drug therapy | |
650 | 2 | |a Brain Ischemia |x drug therapy | |
650 | 2 | |a Blood-Brain Barrier |x drug effects | |
650 | 2 | |a Blood-Brain Barrier | |
650 | 2 | |a Drug Delivery Systems | |
650 | 2 | |a Nanoparticles | |
650 | 2 | |a Nanoparticles | |
650 | 4 | |a MEDICAL ; Pharmacology | |
650 | 4 | |a Drug delivery systems | |
650 | 4 | |a Nanomedicine | |
650 | 4 | |a Nanoparticules | |
650 | 4 | |a Syst�emes d'administration de m�edicaments | |
650 | 4 | |a Barri�ere h�emato-enc�ephalique | |
655 | 0 | |a Electronic books | |
700 | 1 | |a Gao, Huile |4 oth | |
700 | 1 | |a Gao, Xiaoling |4 oth | |
776 | 1 | |z 0128140011 | |
776 | 1 | |z 9780128140017 | |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |t Brain targeted drug delivery systems |d London : Academic Press, ©2019 |z 0128140011 |z 9780128140017 |
856 | 4 | 0 | |u https://www.sciencedirect.com/science/book/9780128140017 |m X:ELSEVIER |x Verlag |z lizenzpflichtig |3 Volltext |
912 | |a GBV-33-Freedom |b 2021 | ||
912 | |a ZDB-33-PTP | ||
912 | |a GBV-33-EBS-MRI | ||
912 | |a GBV-33-EBS-ZHB | ||
912 | |a GBV-33-Freedom |b 2022 | ||
912 | |a ZDB-33-EBS | ||
912 | |a ZDB-33-ESD | ||
912 | |a GBV_ILN_20 | ||
912 | |a ISIL_DE-84 | ||
912 | |a SYSFLAG_1 | ||
912 | |a GBV_KXP | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OPC-PHA | ||
912 | |a SSG-OPC-DE-84 | ||
912 | |a GBV_ILN_22 | ||
912 | |a ISIL_DE-18 | ||
912 | |a GBV_ILN_22_i06404 | ||
912 | |a GBV_ILN_105 | ||
912 | |a ISIL_DE-841 | ||
936 | b | k | |a 58.28 |j Pharmazeutische Technologie |0 (DE-627)106417622 |
951 | |a BO | ||
953 | |2 045F |a 615.1/9 | ||
980 | |2 20 |1 01 |x 0084 |b 1771693185 |c 00 |f --%%-- |d --%%-- |e s |j --%%-- |h ACQ |u CATDESC_ELS-EB |y z |z 04-07-19 | ||
980 | |2 22 |1 01 |x 0018 |b 361644263X |h h64 Elsevier Pharmacology |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots. |y zi06404 |z 31-03-20 | ||
980 | |2 105 |1 01 |x 0841 |b 4074377764 |h OLR-ELV-TEST |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Die Weitergabe an Dritte sowie systematisches Downloaden sind untersagt. |k Testzugang ZHB Lübeck |y z |z 26-02-22 | ||
981 | |2 20 |1 01 |x 0084 |r https://www.sciencedirect.com/science/book/9780128140017 | ||
981 | |2 22 |1 01 |x 0018 |y Volltextzugang Campus |r https://www.sciencedirect.com/science/book/9780128140017 | ||
981 | |2 22 |1 01 |x 0018 |y Nur für Angehörige der Universität Hamburg: Volltextzugang von außerhalb des Campus |r http://emedien.sub.uni-hamburg.de/han/ScienceDirectBookseriesUKE/www.sciencedirect.com/science/book/9780128140017 | ||
981 | |2 105 |1 01 |x 0841 |r https://www.sciencedirect.com/science/book/9780128140017 | ||
985 | |2 20 |1 01 |x 0084 |a 17004989 | ||
985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
995 | |2 20 |1 01 |x 0084 |a ACQ | ||
995 | |2 20 |1 01 |x 0084 |a CATDESC_ELS-EB | ||
995 | |2 22 |1 01 |x 0018 |a h64 Elsevier Pharmacology | ||
995 | |2 105 |1 01 |x 0841 |a OLR-ELV-TEST |